Figure 2.

Percent change from baseline in markers of insulin sensitivity with tirzepatide treatment at 26 weeks. Doses are indicated in figure inset for tirzepatide, dulaglutide, and placebo. Data presented as LSM ± SE at 26 weeks from MMRM; modified intent-to-treat population excluding data after study drug discontinuation or rescue drug initiation. Abbreviations: LSM, least squares mean; MMRM, mixed models repeated measures; SE, standard error. *P < .05 and **P < .001 vs baseline, ^†P < .05 and ^††P < .001 vs placebo, ^‡P < .05 and ^‡‡P < .001 vs dulaglutide.